Suppr超能文献

保留肾单位手术治疗多灶性和遗传性肾肿瘤。

Nephron-sparing surgery for multifocal and hereditary renal tumors.

作者信息

Metwalli Adam R, Linehan William M

机构信息

Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

出版信息

Curr Opin Urol. 2014 Sep;24(5):466-73. doi: 10.1097/MOU.0000000000000094.

Abstract

PURPOSE OF REVIEW

Despite the controversy surrounding the benefits of nephron-sparing surgery, multiple absolute indications for nephron-sparing surgery still exist, including the classic indications of hereditary and bilateral kidney tumors.

RECENT FINDINGS

Multiple genetic mutations have been identified which lead to hereditary kidney cancer conditions. These are briefly reviewed because the surgical management of hereditary kidney tumors depends on the genetic and histologic subtypes involved. Clear understanding of these hereditary conditions is crucial for proper surgical management of these tumors.

SUMMARY

Complex partial nephrectomy for multiple renal tumors, or multiplex partial nephrectomy, requires not only exceptional surgical skills but expertise of numerous nonsurgical methodologies, such as hands-on intraoperative ultrasonography and interpretation of multiple imaging modalities. In addition, multidisciplinary management is crucial for optimal outcomes in patient care. This review evaluates the most advanced surgical techniques and perioperative management required to successfully care for these challenging cases.

摘要

综述目的

尽管围绕保留肾单位手术的益处存在争议,但保留肾单位手术仍有多个绝对适应证,包括遗传性和双侧肾肿瘤的经典适应证。

最新发现

已鉴定出多种导致遗传性肾癌的基因突变。由于遗传性肾肿瘤的手术管理取决于所涉及的基因和组织学亚型,因此对这些突变进行简要综述。清楚了解这些遗传性疾病对于这些肿瘤的正确手术管理至关重要。

总结

对于多发肾肿瘤进行复杂的部分肾切除术,即多重部分肾切除术,不仅需要卓越的手术技能,还需要多种非手术方法的专业知识,如术中亲手操作超声检查以及解读多种影像学检查结果。此外,多学科管理对于患者护理的最佳结果至关重要。本综述评估了成功处理这些具有挑战性病例所需的最先进手术技术和围手术期管理。

相似文献

1
Nephron-sparing surgery for multifocal and hereditary renal tumors.
Curr Opin Urol. 2014 Sep;24(5):466-73. doi: 10.1097/MOU.0000000000000094.
4
Oncological outcomes of partial nephrectomy for multifocal renal cell carcinoma greater than 4 cm.
J Urol. 2010 Jul;184(1):59-63. doi: 10.1016/j.juro.2010.03.035. Epub 2010 May 15.
8
Choice of operation for clinically localized renal tumor.
Urol Clin North Am. 2008 Nov;35(4):645-55; vii. doi: 10.1016/j.ucl.2008.07.002.
9
Outcomes of partial nephrectomy for clinical T1b and T2 renal tumors.
Curr Opin Urol. 2014 Sep;24(5):448-52. doi: 10.1097/MOU.0000000000000081.
10
Genetics of familial renal cancers.
Nephron Exp Nephrol. 2011;118(1):e21-6. doi: 10.1159/000320892. Epub 2010 Nov 11.

引用本文的文献

3
Feasibility and perioperative outcomes of re-operative retroperitoneal robotic partial nephrectomy.
Urol Oncol. 2025 Sep;43(9):525.e1-525.e8. doi: 10.1016/j.urolonc.2025.05.003. Epub 2025 May 27.
5
A Decade of Surgical Management of Renal Cell Carcinoma with IVC Thrombus and Bilateral Renal Tumors: Emphasis on Auto-transplantation.
J Kidney Cancer VHL. 2025 Apr 24;12(2):19-26. doi: 10.15586/jkc.v12i2.367. eCollection 2025.
6
Urinary leak after partial nephrectomy: Insights from a cohort with hereditary, multifocal, and reoperative cases.
Urol Oncol. 2025 Aug;43(8):470.e11-470.e18. doi: 10.1016/j.urolonc.2025.03.013. Epub 2025 Apr 2.
7
Cumulative Impact of Serial Partial Nephrectomy for the Treatment of Recurrent Renal Masses.
J Urol. 2024 Sep;212(3):431-440. doi: 10.1097/JU.0000000000004099. Epub 2024 Jun 12.
8
Sporadic Renal Hemangioblastoma: A Case Report of a Rare Entity.
Cureus. 2023 Oct 16;15(10):e47102. doi: 10.7759/cureus.47102. eCollection 2023 Oct.
9
A novel multiplex score to predict outcomes of partial nephrectomy for multiple tumors.
Urol Oncol. 2023 May;41(5):257.e1-257.e6. doi: 10.1016/j.urolonc.2023.03.007. Epub 2023 Apr 8.
10
A diagnosis of Birt-Hogg-Dubé syndrome in individuals with Smith-Magenis syndrome: Recommendation for cancer screening.
Am J Med Genet A. 2023 Feb;191(2):490-497. doi: 10.1002/ajmg.a.63049. Epub 2022 Dec 13.

本文引用的文献

1
Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management.
J Clin Oncol. 2014 Feb 10;32(5):431-7. doi: 10.1200/JCO.2013.50.8192. Epub 2013 Dec 30.
2
Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases.
Genes Chromosomes Cancer. 2014 Feb;53(2):177-82. doi: 10.1002/gcc.22129. Epub 2013 Nov 15.
3
Parenchymal volume preservation and ischemia during partial nephrectomy: functional and volumetric analysis.
Urology. 2013 Aug;82(2):263-8. doi: 10.1016/j.urology.2013.03.068. Epub 2013 Jun 20.
4
Germline PTEN mutation Cowden syndrome: an underappreciated form of hereditary kidney cancer.
J Urol. 2013 Dec;190(6):1990-8. doi: 10.1016/j.juro.2013.06.012. Epub 2013 Jun 11.
5
A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma.
Mol Cancer Res. 2013 Sep;11(9):1061-1071. doi: 10.1158/1541-7786.MCR-13-0111. Epub 2013 May 24.
6
Germline BAP1 mutations predispose to renal cell carcinomas.
Am J Hum Genet. 2013 Jun 6;92(6):974-80. doi: 10.1016/j.ajhg.2013.04.012. Epub 2013 May 16.
7
Tolerance of the human kidney to isolated controlled ischemia.
J Am Soc Nephrol. 2013 Feb;24(3):506-17. doi: 10.1681/ASN.2012080786. Epub 2013 Feb 14.
8
Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer.
J Urol. 2012 Dec;188(6):2063-71. doi: 10.1016/j.juro.2012.08.030. Epub 2012 Oct 18.
9
Outcomes of patients with surgically treated bilateral renal masses and a minimum of 10 years of followup.
J Urol. 2012 Dec;188(6):2084-8. doi: 10.1016/j.juro.2012.08.038. Epub 2012 Oct 18.
10
Positive surgical margins after nephron-sparing surgery for renal cell carcinoma: incidence, clinical impact, and management.
Clin Genitourin Cancer. 2013 Mar;11(1):5-9. doi: 10.1016/j.clgc.2012.09.010. Epub 2012 Oct 17.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验